By Finance Pulse in Lung Cancer —

J&J's New Therapy Surpasses AstraZeneca's Tagrisso in Lung Cancer Study

Johnson & Johnson's new combination therapy outperforms AstraZeneca's Tagrisso in a lung cancer study. Explore the latest advancements in oncology treatments.

A visually striking image featuring the logos of AstraZeneca and Johnson & Johnson, with a stylized
J&J's New Therapy Surpasses AstraZeneca's Tagrisso in Lung Cancer Study

AstraZeneca's Tagrisso was outperformed by Johnson & Johnson's new combination therapy for lung cancer in a head-to-head study.

Source